EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (RCC) (ANZUP trial 0901).
Ian D. Davis
Consultant or Advisory Role - Bayer (U); GlaxoSmithKline (U); Novartis (U); Pfizer (U)
Research Funding - Bayer; GlaxoSmithKline; Novartis; Pfizer
Val Gebski
No relevant relationships to disclose
Mark D. Chatfield
No relevant relationships to disclose
Peter S. Grimison
Research Funding - Novartis
George Kannourakis
Consultant or Advisory Role - Pfizer
Research Funding - Novartis
Amy L Boland
No relevant relationships to disclose
Jennifer Thompson
Other Remuneration - ANZUP Cancer Trials Group
Martin R. Stockler
Research Funding - Bayer; Novartis